Method for treating patients with ischemic cardiac disease after myocardial infarction |
|
|
IPC classes for russian patent Method for treating patients with ischemic cardiac disease after myocardial infarction (RU 2308982):
Method for treating human diseases accompanied with increased dna content in extracellular spaces of tissues and medicinal preparation for its realization / 2308968
The present innovation deals with treating wide variety of diseases accompanied with increased DNA content in extracellular spaces of human tissues and organs such as: proliferative, for example, tumoral and hyperplastic processes; diseases of infectious origin; diseases being the result of atrophic, degenerative and inflammatory alterations in organs and tissues, for example, systemic lupus erythematosus. The method for therapy includes enteral introduction of DNAase enzyme at the dosages ranged 2000 up to 500000 Kunz U/kg body weight daily. Medicinal preparation for realization of this method contains DNAase enzyme the content of which in a single dosage corresponds to 50000 up to 5000000 Kunz U. It has been first established that enteral introduction of such high dosages of DNAase provides absorption of catalytically valuable quantities of this enzyme into the blood at significant increase of DNA-hydrolytic activity of the enzyme.
 4-fluoro-n-indane-2-ylbenzamide and its using as pharmaceutical agent / 2308946
Invention relates to using 4-fluoro-N-indane-2-ylbenzamide of the formula (I)
![Pyrazolo[1,5-a]pyridines and pharmaceutical agents containing the same](http://img.russianpatents.com/img_data/136/1367492-s.gif) Pyrazolo[1,5-a]pyridines and pharmaceutical agents containing the same / 2308457
Invention relates to new chemical compound of general formula I
 Method of restoring working capacity in sportsmen / 2307682
Method involves affecting with magnet-infrared laser emission. Sportsman is treated by constant magnetic field 35 mTl and pulse IR laser emission 0.89 nm with power density 1 mW/cm. Action is effected consecutively on five zones: heart region, carotid sinus projection, thyroid gland, gall-bladder, kidney and adrenal glands. Action is synchronized with sportsman's chronotype and continued over a 14-21 days period with 1-2 day interval after each 5 sessions. Action is combined with oral administration of alcoholic phytococktail, whose preparation involves elecampane, liquorice, eleuterocock, and aralia included at ratio 2:2:1:1. During first five days, phytococktail is administered in dose of 10-20 drops, which is gradually raised to 30 drops.
White common turpentine emulsion with drug plants having bracing, restorative, and rejuvenating action and method for bath operation / 2307663
Invention relates to agent with bracing, restorative, and rejuvenating action containing emulsion including common turpentine, salicylic acid, baby soap, spirit of camphor, purified water and additionally it contains aqueous extract of drug plants in equal ratio: such as pine and birch buttons; calendula chamomile, and milfoil flowers; marjoram, hunter, thyme, caravan, wormwood, celandine, and mothewort grass; dandelion, all-heal, and calamus roots; fennel fruits; nettle, salvia, ribwort, pepper mint, and eucalyptus leaves in the next component ratio: common turpentine 500.0 g, salicylic acid 3.0 g, baby soap or emulsifier 30.0 g, spirit of camphor 20.0 g, purified water 550.0 ml, and emulsion/aqueous extract of drug plants ratio is from 1 ml per 100 ml to 1 ml per 1000 ml, respectively. Method for bath operation includes addition of claimed emulsion into bath in amount of 10-15 ml per 150 l of water for general bath and 1-2 ml per 10 l of water for topic one at temperature of 36°C. Durability of bath procedure is 15 min at 2-3 h before sleeping. Total course is 25-30 procedures.
Yellow common turpentine solution with drug plants having bracing, restorative, and rejuvenating action and method for bath operation / 2307662
Invention relates to agent with bracing, restorative, and rejuvenating action containing solution including common turpentine, castor oil, oleic acid, sodium hydroxide, purified water and additionally it contains oleic extract of drug plants in equal ratio: such as pine and birch buttons; calendula chamomile, and milfoil flowers; marjoram, hunter, thyme, caravan, wormwood, celandine, and mothewort grass; dandelion, all-heal, and calamus roots; fennel fruits; nettle, salvia, ribwort, pepper mint, and eucalyptus leaves in the next component ratio: common turpentine 500.0 g, sodium hydroxide 13.3 g; oleic acid 150.0 g, castor oil 200.0 g, purified water 133.0 ml, and emulsion/oleic extract of drug plants ratio is from 1 ml per 100 ml to 1 ml per 1000 ml, respectively. Method for bath operation includes addition of claimed solution into bath in amount of 10-15 ml per 150 l of water for general bath and 1-2 ml per 10 l of water for topic one at temperature of 36°C. Durability of bath procedure is 15 min at 2-3 h before sleeping. Total course is 25-30 procedures.
 Method for stimulating of prostaglandin secretion in body / 2307658
Claimed method includes ozonotherapy of patient by ozonation of 100-150 ml patient blood in sterile glass bottle with ozone/oxygen mixture at ozone concentration of 5000 mug/l.
 Prophylaxis composition based on phenolic substances and phospholipids / 2306945
Claim composition useful in prevention or treatment of pathological processes and maintaining of high levels of organism functional activity includes combination of one ore more extracts from medicative herms, containing phenolic substances and phospholipids., wherein phenolic substances are incapsulated into phospholipid capsule. Said phospholipid is selected from group containing phospholipids from bovine or porcine brain or skin, phosphatidylcholine, egg lecitine etc., and capsule is made in form liposome containing 11-40 % of cholesterol. Said phenolic substances are selected from group containing 5,6,7,4'-tetraoxyflavon, 5,6,7-trioxyflavon, gesperidine, etc. Claimed agent is capable of stable aqueous microdispersion formation useful in patentheral administering.
Biologically active agent of wide action spectrum and method for production thereof / 2305546
Claimed agent represents extract obtained by treatment of natural Baltic amber with 40-96 % and further 88-96 % ethanol and contains succinic acid, salts thereof, amber oil, iodol, carbon-oxygen-hydrogen-containing substances, 40-96 % ethanol in specific component ratio. Agent may be performed in form of solution, powder or tablet. Method for production of said agent includes sequential washing of natural Baltic amber with water, then with salt aqueous solution, followed by double extraction with ethanol.
Tissue-specific mitochondrial process control means and method for applying it for treating diseases / 2304978
Method involves extracting means containing a substance possessing light hydrophobic properties negatively charged at alkaline pH from tissues being homologous to tissues under treatment. The substance has molecular mass of 500-15000 Da and is capable of reducing ratio of phosphorylated adenosine phosphate to atomic oxygen quantity consumed by high-energy mitochondria at oxidative phosphorylation stage.
Method for treating pleural empyema cases / 2308894
Method involves determining shape, volume and maximum size of the cavity. Patient body is fixed in position where the maximum cavity size coincides with vertical axis and cavity top and bottom points are determined to introduce draining tubes into them. Metal rod hermetically sealed in glass envelope and alkaline surfactant solutions like 24% Euphilline solution heated to 42°C are introduced into the cavity. Then, the patient is set in position so that the maximum cavity size coincides with horizontal axis and magnetic mixer is brought close from below to patient body surface. Uniform displacement of the metal rod is achieved allover the cavity space under ultrasonic control. The cavity is rinsed until clean solution comes from the cavity. Then, the rinsing procedure is stopped, the rod is removed from the cavity and active suction is applied.
Method for surgical treatment of hydrocephalus / 2307600
One should implant a ventricular catheter into lateral ventricle to withdraw cerebrospinal fluid (CSF) through the drainage system into jejunum. The innovation widens the quantity of means for treating hydrocephalus.
 Catheter for long-time catheterization of main vessels and their branches / 2306958
Catheter can be used for diagnostics and medicinal purposes. Catheter for log-time catheterization of main vessels and their branches is made of plastic tube. Tune has welded end of 3-5 mm length; it has spherical or oval-shaped edge with mirror-smooth surface and with three openings - one main and two ancillary ones. Main opening has cross-section area being equal to 2-3 areas of internal cross-section of plastic tube. Ancillary openings are disposed in opposition along diameter and they are disposed close to main opening in such a way that plane of fluid's efflux out of them should be perpendicular to plane of fluid's efflux from main opening and discharge of liquid through ancillary openings shouldn't excess fluid discharge passing through main opening.
Method for treating gun-shot wounds of limbs' soft tissues / 2306139
On the 1st d after operation a patient should be injected with mexidol intravenously by drops at the dosage of 300 mg, during the next 2 d mexidol should be injected intramuscularly twice daily at the dosage of 200 mg. Moreover, during 10 d after operation a patient should be perorally introduced with ADP-37 preparation a the dosage of 6 capsules daily and during 5 d one should affect the wound with impulse magnetic field at about 0.5-1.0 Tl intensity through Dalcex-trypsin filter cloth impregnated with 0.01%-serotonin solution, once daily. The innovation enables to accelerate the terms of wound healing up to 6-7 d and avoid therapy-induced complications.
 Catheter for removing containers filled with tissues of gut at laparoscopic operations / 2304986
Catheter for removing containers having tissues from cavity of gut at laparoscopic operations is made elastic and hollow. It has loops, head and handle-clamp. Loops are disposed at proximal end of catheter and they are made for pull up and tight after forward part of container is placed in them. Hear is fastened to distal end. Handle-clamp consists of two semi-cylinders connected by hinge and lock. Handle is made for connection with distal end by means of catheter after catheter goes outside.
Method for treatment of patients with locally spread squamous cell larynx cancer / 2303446
Method involves carrying out the preliminary catheterization of larynx artery and the following intra-arterial chemotherapy by administration of cisplatin as 6 h infusion of 80-100 ml of 0.0025% solution from 1-st to 4-th day of treatment in the total dose 100 mg/m2, 5-fluorouracil as 3 h infusion of 20 ml of 5% solution from 5-th to 7-th day of treatment in the total dose 3 g. After termination of chemotherapy in 2-3 weeks after arresting adverse reactions in tumor regression above 50% the larynx resection is carried out and in regression less 50% - laryngoectomy. In 3-4 weeks after surgery operation the distance radiation therapy is carried out in a single irradiation dose 2.0 Gr in irradiation regimen 5 times per a week and in the total dose 40-46 Gr in laryngoectomy and 60-66 Gr in organ-retaining surgery operation depending on the stage of the primary process. Method provides the functional rehabilitation of patients and decreasing expression and amount of total complications of complex therapy based on step-by-step carrying out the treatment. Invention can be used in treatment of patients with locally spread squamous larynx cancer.
 Method for carrying out accurate drug delivery to deep lesion foci in abdominal cavity organs / 2299747
Method involves introducing flexible tube into the abdominal cavity with injection needle being attached without cannula to one of its ends and needle cannula being attached to the other end. Fluoroplastic tube is caught by means of manipulator on the needle boundary. Organ is punctured under vision control. Drug solution is introduced into organ parenchyma without removing the manipulator.
Method for carrying out transluminal laser-induced brain revascularization in atherosclerotic injury cases / 2297861
Method involves puncturing and catheterizing general femoral vein or general carotid by applying Seldinger techniques. Introducer of 4-9F in diameter set. Conducting catheter is coaxially introduced through it into the injured cerebral bloodstream bed. Radiopaque flexible catheter of 3-6F in diameter with light guide is coaxially introduced through it to blood vessel occlusion place. Flexible quartz - quartz or quartz-polymer light guide diameter is equal to 100-200 mcm. Heparinized physiological salt solution is introduced during laser installation operation at a rate not less 0.1 ED of heparin in 1 ml of physiologic saline. Solution introduction rate is not less than 1 ml/s. Then, the conducting catheter brought down. The distance between light guide end face and irradiated surface is 1-5 mm long. High-energy laser of 20 W power is applied. Pulsating periodic pulsating mode is applied. Radiopaque substance is periodically introduced in small dozes and carry out during laser radiation treatment and X-ray TV control over passability and full-scale lumen restoration in the injured bloodstream bed zone.
Method for endovascular treatment of alzheimer's disease / 2297860
According to a certain technique one should puncture and catheterize a total femoral artery along with applying an introducer of 6-9 F diameter. Through this introducer one should coaxially apply and install the first conductor catheter of 5-8 F diameter and modeled distal part in the trunk of the inner carotid artery; through it is necessary to coaxially apply the second modeled conductor catheter of 4-5 F diameter to be superselectively installed in median cerebral and anterior cerebral arteries. Successively, through it one should coaxially apply a flexible roentgenocontrast catheter of 2-3.5 F diameter with a movably located flexible quartz-quartz or quartz-polymeric light guide at diameter of light-conducting fiber ranged 50-100 mcm and total diameter of about 300-400 mcm. The light guide should be moved along the vessel towards the site of microcirculatory vascular tract lesion in distal departments. The first conductor catheter should be descended and applied in descending part of aortic arch, the second one should be descended and applied in proximal part of total carotid artery. Then it is necessary to affect with low-energy laser, the power being 20 mW, the mode should be either uninterrupted, or impulse, or combined. During irradiation it is important to introduce heparinized physiological solution at 0.1 U heparin/ml physiological solution, the rate of injection corresponds to 0.1 ml/sec, not less. The innovation enables to reconstruct microcirculatory vascular tract in brain along with regeneration of surrounding cerebral tissues.
Method for chemoradiation therapy of brain malignant glial tumor / 2296567
Method involves carrying out lumbal puncture to a patient in post-operative period, subarachnoid space is catheterized, and 5 ml of liquor is removed followed by incubation of liquor with nimustine taken in the dose 5 mg in vitro at temperature 38°C for 30 min, and liquor is administrated into subarachnoid space through catheter. Procedure is carried out 2 times with interval for 7 days. Since the second day after onset of this procedure distant gamma-therapy on bed of removed tumor is carried out up to the total focus dose 60 Gr. Method provides stable remission, decreasing toxicity of chemopreparation, frequency of adverse by-side effects and significant reducing the cost of chemotherapy. Invention can be used in carrying out the adjuvant chemoradiation therapy of brain malignant glial tumors.
Method for treating hodgkin's lymphoma / 2304968
It is necessary to fulfill the puncture of posterior section of iliac ala to sample 150 ml medullary suspension into the vial with 50 ml hemoconservant. The vial's content should be supplemented with 40 mg/sq. m doxorubicin, 600 mg/sq. m cyclophosphan and 1.4 mg/sq.m vincristine. The mixture obtained should be incubated at 37°C for 40 min. Then this mixture should be injected for a patient intravenously by drops. Then it is important to conduct infusion of 375 mg/sq.m dacarbazine on the 1st d of therapy. Since the 1st to the 10th d they prescribe per 40 mg/sq. m prednisolone. On the 8th d of therapy one should intravenously inject 10 mg/sq. m bleomycin. The course should be repeated in 14 d. The innovation enables to apply automyelochemotherapy on the 3d-4th stage of systemic malignant disease as the main type of therapy by preventing the increased rate of aseptic necroses of capuit femoris in this category of patients due to the matched injection scheme.
|
FIELD: medicine, cardiology. SUBSTANCE: it is necessary to carry out medullary aspiration out of iliac crest to isolate autologous mononuclear medullary cells due to gradient centrifuging. They should be delivered into area of post-infarction myocardial necrosis due to introducing into coronary artery. Moreover, cellular suspension should be infiltrated into area of myocardial necrosis without preliminary cultivation at the quantity of about 70-110 mln. cells. For this purpose one should introduce a microcatheter into coronary artery so that arterial diameter and that of a microcatheter should coincide and it is necessary to supply the cells through it under the pressure of 2 atm. The innovation suggested enables to increase the quantity of mononuclear cells deposited in myocardium and decrease balloon's damaging impact upon the wall of coronary artery during introducing cellular suspension. EFFECT: higher efficiency of therapy. 1 ex
The invention relates to the field of medicine, particularly cardiology, and relates to a method of treating coronary heart disease (CHD), myocardial infarction. Heart failure is the end point of the disease patients with this pathology [1, 2, 3]. Heart transplantation remains the only radical method of treatment of end-stage heart failure. However, the shortage of donor complications associated with immunosuppressive therapy, are major limitations of this method of treatment [3, 4]. This makes the search for new alternative approaches, which include cell transplantation [5]. There is a method of treatment of patients with ischemic heart disease, myocardial infarction [6], when the infarct - related coronary artery is injected with a suspension of autologous mononuclear bone marrow cells that were pre-cultured for days with autologous blood plasma, on the 7th day during repeated coronary angiography, the introduction of cell suspension takes place during occlusion of the lumen of the coronary artery by the balloon. This method is the closest to the claimed technical essence and the achieved result and selected as a prototype. The disadvantage of this method is the necessity of using additional container during the introduction of the tile is offered by the mist, that may increase the risk of complications of interventional procedures, and the need for culturing autologous mononuclear bone marrow cells with autologous blood plasma during the day. The purpose of the invention is improving the effectiveness of treatment by increasing the amount deposited in the myocardium of mononuclear cells and reduce the risk of complications of interventional procedures by reducing the damaging effects of balloon on the wall of the coronary artery during injection of the cell suspension. This goal is achieved technical solution that represents a method for the treatment of patients with coronary artery disease, myocardial infarction, involving the introduction of a suspension of autologous mononuclear bone marrow cells without cultivation in the coronary artery supplying the area of myocardial infarction. The cell suspension is injected in the amount of 70-110 million cells. There is no need to use the container for occlusion of a coronary artery during injection of cell suspensions, the jamming of the coronary artery to produce a microcatheter, which deliver mononuclear cells in the bone marrow. Aspiration of bone marrow conduct of the iliac crest after the puncture her predavanja barb. Autologous mononuclear bone marrow cells secrete the method of gradient centrifuge the Finance. New in the proposed method is the introduction of cell suspension in the number of 70-110 million cells without prior cultivation that does not require additional costs, under a pressure of 2 ATM after jamming artery multipurpose nylon for infusion microcatheter with a diameter of 1.0 to 1.5 mm, length 150 see a Pressure of 2 ATM allows you to infilterate myocardium without damaging the wall of the coronary artery. Distinctive features showed in the inventive combination of new properties that are not explicitly derived from the prior art in this field and obvious to the specialist. Identical set of features in proanaliziruesh patent and scientific and medical literature is not detected. The proposed solution can be used in health care. Based on the foregoing should be considered as the invention with the relevant conditions of patentability: Novelty", "Inventive step", "Industrial applicability". The method is as follows: under local anesthesia with 0.5%solution of novocaine dotted line in the iliac crest in the area of predavanja spine, aspirinum 100-120 ml of bone marrow in two 60-ml syringe with 4 ml of heparin and 6 ml of physiological solution of 0.9% NaCl, with the method of gradient centrifugation allocate mononuclear cells in the bone marrow. otomat suspension of mononuclear bone marrow cells with a concentration of from 2 to 5 to 10 6cells in 1 ml of Performing coronary angiography, then set the microcatheter into the coronary artery so that the artery diameters and microcatheter coincided and was jamming the coronary artery, then carry out the introduction of a suspension of mononuclear bone marrow cells under a pressure of 2 ATM, which leads to infiltration of the myocardium introduced cells. Example. Patient R., aged 44, was admitted to the Department of cardiovascular surgery, Institute of cardiology, Tomsk scientific 6 months after myocardial infarction. The patient perform a standard examination. According to the stress perfusion scintigraphy of the myocardium with thallium 199 reveal stable 38% passing 15% defects in myocardial perfusion. In addition, establish a reduced ejection fraction of the left ventricle to 42%. When performing coronary angiography revealed stenosis of the anterior interventricular artery and perform stenting of stenoses. On the 14th day after admission to hospital under local anesthesia with 0.5%solution of novocaine dotted line in the iliac crest in the area of predavanja spine, aspirinum 100 ml of bone marrow, the method of gradient centrifugation produce autologous mononuclear bone marrow cells, perform coronary angiography, kateteriziruyut the mouth of the anterior interventricular artery, spend Microcat the Ter 1 mm to match the diameter of the catheter and artery, jam anterior interventricular artery and under a pressure of 2 ATM impose a suspension of mononuclear bone marrow cells in the amount of 80 million in 20 ml of physiological solution of 0.9% NaCl with the addition of a contrast agent omnipaque-350 (Nycomed, Ireland). Media fixed delay of contrast in the myocardium of about 60 seconds. The video archive in digital format Dicom. All these interventions the patient tolerates well, there have been no complications. After treatment, the patient is followed over 6 months and state the positive results of the treatment, which is manifested by a decrease in end-diastolic volume of the left ventricle, increased ejection fraction of the left ventricle, decreasing the amount of stable perfusion defect by 15%. During the observation period do not exhibit clinical signs of chronic heart failure. The proposed method was applied in 8 patients and showed that by reducing the risk of complications during their time increasing the efficiency of treatment of patients with ischemic heart disease, myocardial infarction, by reducing the severity of processes postinfarction remodeling of the left ventricle, improving contractile function and myocardial perfusion. References 1. McMurray JJ, Stewart S. Epidemiology, aetiology and prognosis of heart falure. Heart 2000; 83(5): 596-602. 2. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J 1999; 20(6): 421-428. 3. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engi J Med 2002; 347(18): 1397-1402. 4. Kherani AR, Garrido MJ, Cheema FH, et al. Nontransplant surgical options for congestive heart failure. Congest Heart Fail 2003; 9(1): 17-24. 5. Dimarakis I, Nagy A. Habib, Myrtle Y.A. Gordon. Adult bone marrow-derived stem cells and the injured heart: just the beginning? Eur J Cardiothorac Surg 2005; 28: 665-676. 6. B.E. Strauer, Brehm m, Zeus T., et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106: 1913-1918. Method of treatment of ischemic heart disease, myocardial infarction, consisting of bone marrow aspiration from the iliac crest and the allocation of autologous mononuclear bone marrow cells by the method of gradient centrifugation and their delivery in the area of post-infarction necrosis of the myocardium by injection into the coronary artery, wherein the cell suspension without prior cultivation in the number of 70-110 million cells infiltrate into the zone of necrosis of the myocardium, while installing the microcatheter into the coronary artery so that the artery diameters and microcatheter coincided, and served through him at the cells under a pressure of 2 ATM.
|